Postnatal depression ‐ not measured · women diagnosed with gestational diabetes; 11 to 33 weeks' gestation; singleton pregnancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Induction of labour ‐ not reported · women diagnosed with gestational diabetes; 11 to 33 weeks' gestation; singleton pregnancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Large‐for‐gestational age · women with gestational diabetes mellitus
Glibenclamide showed no clear difference in large‐for‐gestational age compared with acarbose ‐ neonatal outcomes (low certainty).
1 finding from 1 review
Perinatal mortality · women with gestational diabetes mellitus
1 finding from 1 review
Death or serious morbidity composite · women with gestational diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neonatal hypoglycaemia · women with gestational diabetes mellitus
Glibenclamide showed no clear difference in neonatal hypoglycaemia compared with acarbose ‐ neonatal outcomes (low certainty).
1 finding from 1 review
Adiposity ‐ not reported · women with gestational diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Diabetes ‐ not reported · women with gestational diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neurosensory disability in later childhood ‐ not measured · women with gestational diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Substantial benefit: At least 50% reduction in pain, or PGIC much improved · adults with fibromyalgia
It is very uncertain whether NSAID changes substantial pain relief: at least 50% reduction in pain, or PGIC… compared with placebo (very low certainty).
1 finding from 1 review
Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with fibromyalgia
It is very uncertain whether NSAID changes moderate pain relief: at least 30% reduction in pain, or PGIC much… compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Withdrawals due to adverse events · adults with fibromyalgia
It is very uncertain whether NSAID changes adverse event withdrawal compared with placebo (very low certainty).
1 finding from 1 review
Number experiencing adverse effects · adults with fibromyalgia
It is very uncertain whether NSAID changes participants experiencing any adverse event compared with placebo (very low certainty).
1 finding from 1 review
Withdrawal (all‐cause) · adults with fibromyalgia
It is very uncertain whether NSAID changes all cause withdrawal compared with placebo (very low certainty).
1 finding from 1 review
Death · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Participants with at least 30% or at least 50% reduction in pain · people with cancer pain
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
PGIC much or very much improved · people with cancer pain
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Mean pain intensity at end of study · people with cancer pain
1 finding from 1 review
Intervention not reported
Pain no worse than mild at one or two weeks (or equivalent) · people with cancer pain
1 finding from 1 review
no estimate extracted
Studies not reported
Very low